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Abstract:  
Pyridostigmine is a reversible acetylcholinesterase inhibitor that has been used to help 
treat myasthenia gravis and reduce nerve agent effects. By reversibly binding to 
acetylcholinesterase, Pyridostigmine causes elevation of acetylcholine, which is 
beneficial in disease states where increased contractility is needed. The present study 
relates to the investigation of Pyridostigmine to treat cardiac patients. A sensitive and 
specific liquid chromatography tandem mass spectrometry (LC-MS/MS) method was 
developed to detect Pyridostigmine in plasma samples from study participants dosed with 
this drug. The method was validated according to Scientific Working Group in Forensic 
Toxicology (SWGTOX) guidelines and used to quantify the amount of Pyridostigmine in 
the patient plasma samples. Solid phase extraction (SPE) was used to extract the drug 
from the plasma matrix. The SPE and LC-MS/MS method successfully quantified 
Pyridostigmine in the study participants, facilitating the development of a dosing model 
by research partners. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 Recently, the Oklahoma State University Center for Veterinary Health Sciences needed a 
method to quantitate Pyridostigmine (PYR) in the plasma of heart patients in a clinical trial they 
were supporting. In response, a method was developed that utilized solid phase extraction (SPE) 
followed by liquid chromatography tandem mass spectrometry (LC-MS/MS). Following 
development, this method was validated as being sensitive and selective for PYR in human 
plasma. This method provides the means to quantify PYR, which is necessary to develop models 
to determine proper dosing for patients treated with this drug.  
 Previous literature shows that PYR induces cholinergic stimulation, which in turn 
increases heart rate,1 reduces ventricular arrhythmias,2 and blunts the cardiac responses to mental 
stress.3 These studies provide cardiac test results that indicate PYR is improving cardiac function. 
Literature also exists that provides methods to detect PYR in rat urine and guinea pig plasma, but 
not in humans using LC-MS/MS.4,5 This literature indicates that PYR can help with cardiac 
function and that it has the potential to be accurately measured in human biological specimens. 
 This method was necessary to support a dosing study for PYR. The studies providing 
methods to detect PYR only do so for animal specimen or human specimen using only ultraviolet 
detection techniques. Also, no study exists that provides an LC-MS/MS method to detect and 
quantify PYR in human plasma.
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
2.1 Introduction 
 The topic for this research project is the development and validation of a solid phase 
extraction (SPE) and liquid chromatography tandem mass spectroscopy (LC-MS/MS) method to 
detect and quantify Pyridostigmine (PYR) in plasma samples. Patients involved in the clinical 
trial were administered PYR in an attempt to help improve cardiac function. Then, after the 
patients had completed heart stimulating physical activity, blood samples were taken during 
specific time increments. Development of a method to detect the amount of PYR in the 
bloodstream following controlled administration can help provide information about the 
pharmacokinetics and pharmacodynamics of PYR. 
2.2 Background 
 PYR is a complex drug that has been used for many treatments. Its function in the body is 
as an acetylcholinesterase (AChE) inhibitor. As an AChE inhibitor, PYR has been used to help 
treat the symptoms caused by myasthenia gravis. This drug has also been used to help protect 
against nerve agent effects. Most recently, PYR has been used to try to help improve cardiac 
function.  
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 2.2.1 PYR as an AChE Inhibitor 
 As mentioned, PYR is an AChE inhibitor. Cholinesterase inhibitors are compounds that 
keep the enzyme AChE from functioning. During neurotransmission, acetylcholine (ACh) is 
released from the nerve into the synaptic cleft and binds to the nicotinic and muscarinic ACh 
receptors on the post-synaptic membrane relaying the signal from the nerve. For the body to 
perform any action, neurons have to be sent to the location in the body that the action will take 
place. When these neurons reach the presynaptic nerve, ACh goes and binds to its receptors, 
which release the secondary messages to initiate the given action. Once the secondary messages 
have been relayed, ACh has completed its part in relaying the action signal. ACh must then be 
removed, and that action is completed by AChE. The enzyme AChE is responsible for breaking 
ACh down into acetate and choline molecules. The choline molecules are recycled and reused to 
make more ACh to put in storage for future actions. In summary, ACh molecules are used by the 
body to initiate action signals.6  
 However, if AChE’s function is inhibited, the ACh molecules will accumulate and cause 
an increase of action signals. The enhanced stimulation caused by this accumulation will cause 
the body to continue the action that is being signaled without ceasing. This increase in signal can 
have both negative and positive effects. Cholinesterase inhibitors, due to their effect in the 
signaling pathway, can be used as both toxic agents and aids for specific diseases. These 
inhibitors are also used to help prevent against chemical warfare. Pope et al discuss several 
aspects of cholinesterase inhibitors to educate readers on their affect in the body and to provide 
insight into their potential.7 These aspects discussed by Pope et al include the history of 
cholinesterase inhibitors and the development of the mechanism of action for these compounds. 
Other aspects include the pharmacology and toxicology of these inhibitors and their use as drugs 
for specific diseases and chemical warfare prevention. The final aspects provide examples of 
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many drugs and their specific mechanisms of action as cholinesterase inhibitors and research 
study examples that demonstrate the effectiveness of these inhibitors.7 
 Both reversible and irreversible AChE inhibitors exist. PYR is a reversible inhibitor. 
Reversible inhibitors will bind to AChE for a short period of time, causing AChE to lose its 
function, but will eventually undergo decarbamylation. The decarbamylation causes PYR or any 
other reversible inhibitor to be released from AChE. Once the reversible inhibitor has been 
removed, AChE regains its function and begins to break down the ACh that has built up in the 
synapse. However, there are irreversible inhibitors. One example of irreversible inhibitors is 
organophosphorous compounds, which can be used as nerve agents. These compounds bind to 
AChE and permanently inhibit its function. When AChE completely loses its ability to break 
down ACh, those secondary receptors become overstimulated causing involuntary movements, 
excessive secretions, and respiratory dysfunction. Exposure to these compounds can cause acute 
toxicity, death, or other severe long-term effects like psycho-motor functioning impairment.6 
 Rang et al discuss cholinergic transmission in their book on pharmacology.8 Since PYR is 
an AChE inhibitor, it affects the cholinergic transmission process. As mentioned before, AChE is 
an enzyme responsible for breaking down ACh after it has been used to help signal an action. 
This chapter discusses this process as well as what happens when an inhibitor is introduced. This 
chapter is helpful because it provides the pharmacology foundation necessary for an 
understanding of the action of this drug.8 
 2.2.2 PYR as a Treatment for Myasthenia Gravis  
 As an AChE inhibitor, PYR affects the nervous system. Ropper et al wrote a chapter on 
myasthenia gravis, which is a neuromuscular junction disorder that is treated by PYR. 
Myasthenia gravis translates to mean “grave muscular weakness.” This chapter by Ropper et al 
discusses PYR’s uses for treatment as well as the history of the disease.9 Also, the medical 
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encyclopedia on MedlinePlus has a section discussing myasthenia gravis. As mentioned 
previously, PYR is a drug used to help treat people with this disorder. This source provides the 
background information on the disorder, which is helpful for understanding the full impact of this 
drug on the people who take it.10 
 The first use for PYR was for the treatment of myasthenia gravis. This disease causes 
fluctuating weakness of the voluntary muscle groups, which are all of the muscle groups that can 
be controlled. The fluctuating weakness occurs because a person with myasthenia gravis produces 
antibodies that target the ACh receptors and cause them to degrade. The degradation of receptors 
results in a loss of sites for ACh to bind. When the body sends neurons to designate a specific 
action after a loss of receptor sites, ACh will have difficulty finding somewhere to bind to 
continue the signaling pathway for that action to happen. A decrease in signal causes the muscle 
weakness. When a patient takes PYR, the resulting accumulation of ACh will cause the signaling 
to reach almost normal levels. The increased number of neurotransmitters in the synapse 
compensates for the loss of receptor sites.11  
 A supplement to an article by Zha et al in Neurology features the abstract for a study that 
used PYR to help treat patients that had been exposed to botulinum toxin.12 The abstract contains 
the study’s objective, background, method, results, and conclusion. Since PYR has been shown to 
be effective in patients with myasthenia gravis, the hope for this study was that PYR could be 
used to help treat the long-term effects of botulin toxicity. Currently, the abstract is the only part 
of this article that can be found. The goal is to retrieve the entire article as soon as it is released to 
read their full discussion on the treatment, use, and effect of PYR in this study.12 
 2.2.3 PYR as a Protection Against Nerve Agents 
 Shortly after PYR’s use for myasthenia gravis was discovered, the Gulf War began. With 
the war came worry and fear of nerve agents being used in combat. Since PYR is a reversible 
6 
 
AChE inhibitor, scientists discovered that it could be used to bind to AChE to prevent the 
irreversible binding of nerve agents. PYR acts as a shield against nerve agents. These 
organophosphorous compounds, as discussed before, bind to AChE and permanently inhibit its 
function. However, if the nerve agents arrive and PYR is already bound to the AChE enzyme, 
then the nerve agents will not be able to bind. By blocking the enzyme against nerve agents, PYR 
protects AChE from permanent inactivation.13 As the Gulf War began and the threat of nerve 
agents spread, PYR for the soldiers was given to the commanding officers in 21 pill packets. Each 
pill was 30 mg, to be taken three times a day. The commanding officer was responsible for 
determining whether the soldiers took the medicine. If the officer thought there was a threat for 
nerve agent attack, then the soldiers would be commanded to begin taking the regimental dose.14 
PYR, however, was not the soldier’s only defense against nerve agents. On their person, each 
soldier carried atropine and was instructed to self-inject it into the bloodstream upon any 
encounter with a nerve agent. So these two drugs in combination were the defense against nerve 
agent intoxication.13  
 After the conclusion of the Gulf War, a study conducted by Abou-Donai et al looked at 
the effects of taking PYR.15 This study focused on three different chemicals, one being PYR, to 
see if there could potentially be lasting effects from exposure to people using these chemicals for 
their respective protections. Abou-Donai et al used animal models to observe the effects over a 
60-day period. No animal died after taking or being exposed to any of the individual three 
chemicals. However, animals taking any combination of these chemicals have mortality rates 
ranging from 20 to 80 percent. The study provides valuable information about PYR’s use as a 
nerve gas agent and the potential long-term effects that soldiers could face from taking PYR for 
their protection.15  
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 2.2.4 PYR as an Aid for Cardiac Function 
 The new use for PYR is as an aid for cardiac function. A study by Durand et al used 
pyridostigmine on mice during an experience of cardiac arrest.16 The researchers induced a heart 
attack in each mouse and then administered PYR as a treatment in the following days and weeks. 
Researchers observed that this drug was able to preserve the cardiac autonomic balance, which is 
a positive result. This study provides hope that PYR could be used on human patients who have 
weaker hearts or who have suffered heart attacks. The patient plasma samples received were from 
patients taking the drug to help with cardiac function. This article provides insight as to how and 
why this drug could help.16 
 2.2.5 PYR Studies 
 Several studies have been conducted to analyze for PYR. In an article by Zhao et al, 
studies from 1975 to 2005 were discussed and compared that were for detecting PYR and its 
metabolites in biological samples. These biological samples included plasma and urine from rats 
and humans, plasma from guinea pigs, and serum from humans. The extraction methods used in 
these studies were either solid phase extraction or liquid-liquid extraction. Detection assays used 
within these studies were HPLC, ultraviolet (UV) techniques, gas chromatography, and mass 
spectrometry. All human plasma studies detected PYR using UV techniques.17 No studies were 
mentioned that detected PYR using LC-MS/MS instrumentation. 
 The guinea pig study mentioned in the Zhao et al article was conducted by Needham et al 
and publish in the Journal of Chromatograph B in 2003. This study used LC-MS/MS 
instrumentation to detect for PYR in guinea pig plasma. The plasma samples in this study were 
prepared using a protein precipitation extraction with acetonitrile. Linearity, accuracy, precision, 
specificity, selectivity, stability, extraction recovery, and matrix effects studies were performed 
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for the method used in this study. Each of these method studies was successful, which means that 
the method used to analyze for PYR is acceptable and trustworthy.5  
2.3 Laboratory Techniques 
 To help prove that PYR has made it into the bloodstream to aid in cardiac function, an 
extraction and LC-MS/MS method needed to be developed. A study conducted by Abu-Qare and 
Abou-Donai developed a method to detect Pyridostigmine and other drugs in rat plasma and urine 
samples. The researchers used a liquid-liquid extraction to separate the drugs from the plasma and 
urine. They analyzed these extracted samples using a high performance liquid chromatography 
(HPLC) instrument. This study can be a helpful reference as the PYR LC-MS/MS method for 
analysis is developed.18 
 2.3.1 LC-MS/MS  
 An LC-MS/MS method provides a way to separate and detect specific compounds. The 
LC portion separates compounds in a mixture so that they are easier to analyze and detect. The 
MS instrument is set to detect specific mass-to-charge ratios that accompany compounds; so 
when the compounds leave the LC column and hit the MS, the computer will know exactly which 
compound is being detected. The Principles of Forensic Toxicology provides several chapters that 
discuss how the LC and MS function. The chromatography chapter provides useful information 
on several key steps in the LC process. These key steps include mobile phase solution, chemical 
separation, and instrument detection information.19 The chapter on mass spectrometry provides 
information on all of the processes that occur within the MS instrument during chemical 
analysis.20 Having an understanding of the instrumentation being used is important for any 
researcher. These chapters will be a great resource to solidify current knowledge on how these 
instruments work. 
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 2.3.2 Solid Phase Extraction (SPE) 
 An extraction method provides the mechanism for separating a drug from the specimen 
matrix in which it arrives. For this project, the drug is PYR and the matrix is plasma. The LC-
MS/MS instruments are sensitive and expensive. If pure plasma samples were injected into these 
instruments, the tubing would clog and have to be replaced after each run. As a means to save 
time and money, extraction methods separate the desired drug from all other parts of the 
specimen. The extraction method used for this project will be a SPE. The books Principles of 
Forensic Toxicology and Forensic Chemistry provide insight into the SPE process. Siek in 
Principles of Forensic Toxicology provides a short section in his specimen preparation chapter on 
SPE. In this section, Siek discusses the advantages for using SPE. He also provides the steps 
necessary to successfully complete a SPE experiment.21 Bell in Forensic Chemistry provides an 
in-depth analysis on the SPE column and the way that this column works to separate chemicals. 
Bell’s chapter has a detailed figure on SPE procedures and a well-organized table on solvent 
strength, which are both key pieces of information to know before developing any SPE method.22 
These chapters will be a guide for building the SPE method. 
2.4 Conclusion 
 Development of an extraction and LC-MS/MS method for the detection of PYR was 
needed to help prove the effectiveness and efficiency of PYR with cardiac patients. Originally, 
PYR was developed and used to help treat myasthenia gravis by increasing muscle function. Due 
to PYR’s ability to reversibly inhibit AChE, it was then used as prevention for nerve agent attacks 
during the Gulf War. Now, PYR is being tried as a treatment to help improve cardiac function in 
patients with weak hearts. The development of this detection method is a necessary step in the 
process of providing evidence that PYR is useful as an aid for cardiac patients. 
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CHAPTER III 
 
 
METHODOLOGY 
 
3.1 Introduction 
 The experimental methodology for this study was developed to analyze pyridostigmine 
bromide (PYR) in plasma. This method consists of an extraction followed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis. Adherence to the Oklahoma 
State University Institutional Review Board rules were met by filing a form to request for the 
determination of non-human subject research because this study involved de-identified human 
specimen. The purpose of this study was to develop an LC-MS/MS method to accurately detect 
and quantify the amount of PYR in cardiac patient plasma samples.  
3.2 Materials 
 Materials used for this method included the reagents, drug standards, other chemicals, 
plasma and laboratory equipment. Methanol from J.T. Baker Chemicals (Avantor Performance 
Materials, Center Valley, PA), acetonitrile from EMD Millipore (Darmstadt, Germany), and
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formic acid from EMD Chemicals (Gibbstown, NJ) were all HPLC grade reagents. The PYR 
standard was from USP (Rockville, MD), and the internal standard (neostigmine bromide) was 
from Sigma-Aldrich (St. Louis, MO). Other chemicals used in this method include ammonium 
formate from Alfa Aesar (Ward Hill, MA), citric acid from VWR International (West Chester, 
PA), and dibasic anhydrous sodium phosphate from AMRESCO (Solon, OH). Pooled normal 
human plasma was obtained from Innovative Research (Novi, MI).  
 The laboratory equipment used for this study included a VWR B2500A-MTH sonicator, 
an Eppendorf Centrifuge 5424, a SPEware Cerex 48 Positive Pressure SPE, and a SPEware Cerex 
48 Sample Concentrator. Both SPEware instruments were connected to a nitrogen gas cylinder. 
Other materials used are Oasis WCX 3cc, 60mg, 30μm cartridges from Waters, 0.45μm SFCA 
Nalgene syringe filters from Thermo Scientific, 15mL centrifuge tubes with flat caps (falcon 
tubes) from VWR, 13 x 100 culture tubes, 1.5mL centrifuge tubes, 1.5mL autosampler vials with 
caps, and 150μL vial inserts.  
3.3 Reagent Preparation 
 The reagents needed for the sample preparation include a 50mM citrate phosphate buffer 
solution and a citrate phosphate internal standard solution. The citrate phosphate buffer solution is 
made by combining 60.6mL of a 0.2M dibasic sodium phosphate solution with 39.4mL of a 0.1M 
citric acid solution. This combined solution is then diluted with 100mL of deionized water to 
make a 50mM citrate phosphate buffer solution. For the internal standard solution, 2.5μL of a 1 
mg/mL neostigmine bromide stock solution made in a 1% formic acid in methanol solution is 
added to 24.997 5 mL of the 50mM citrate phosphate buffer solution. A 1 mg/mL PYR solution 
made in a 1% formic acid in methanol solution is used to make the 5000 ng/mL PYR stock 
solution that preps the calibration curve.  
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 Mobile phase A (MPA) and mobile phase B (MPB) solutions are need for the LC 
instrument and the sample diluent. MPA is 1000mL of a 50mM ammonium formate solution at a 
pH of 3.25 in deionized water. MPB is a mixture of 500mL acetonitrile and 500mL methanol. 
The sample diluent is made by adding 3mL of MPA to 7mL of MPB. An elution buffer to pull 
PYR off of the solid phase extraction (SPE) column is made by combining 80mL of methanol and 
20mL of a 1.5% formic acid solution in water. 
3.4 Instrumentation 
 The instrumentation for this project included a Shimadzu HPLC system with a SCIEX 
4000 Q-Trap mass spectrometry unit. Analyst® software and MultiQuant® software were used to 
control the instruments and perform data analysis. The column used in the LC system was a 
Restek Ultra PFPP. The entire LC-MS/MS instrument can be seen in Figure 1.  
Figure 1. LC-MS/MS Instrumentation 
 
This figure shows the entire LC-MS/MS instrument. The liquid chromatography instrument is on the far 
left of the picture and has the mobile phase solutions sitting on top. The mass spectrometry instrument is 
located on the right side of the picture. Both instruments are connected with tubing that allows the injected 
solutions to flow from the LC to the MS. 
13 
 
3.5 Extraction 
 An extraction is necessary for this method to separate PYR from any other chemicals that 
could be in the plasma matrix that it comes in. The extraction portion of this method also cleans 
up the sample that is injected onto the LC-MS/MS instrument. A clean sample keeps the tubing 
and column from clogging too quickly, which saves both time and money.  
 3.5.1 Calibration Curve Preparation 
 Pooled normal human plasma or blank plasma is used to prepare the standard curve 
samples in the calibration curve. The blank plasma arrives in a 100mL container, which is divided 
into 10mL portions in labeled falcon tubes. The blank plasma is stored in the freezer, so it must 
be set out to thaw at room temperature for about an hour before the process can begin. After the 
plasma has thawed, the plasma samples in the falcon tubes are placed in the sonicator for 20 
minutes to separate the plasma from the proteins and clotting factors that could clog the 
extraction column. The sonicated plasma samples are then transferred to eppendorf tubes each 
containing approximately 1mL of plasma and then centrifuged to separate any leftover 
components from the plasma. The left behind clotting factors and proteins from the plasma were 
then discarded. Afterward, these plasma samples are filtered into culture tubes and ready to be 
used to prepare the calibration curve standards. 
 The standard curve is prepared by following the instructions from Table 1. 
Concentrations in the standard curve range from 1 to 50 ng/mL with quality control samples at 
concentrations of 5, 15, and 40 ng/mL. The 50 ng/mL standard is prepared first using the 5000 
ng/mL PYR stock solution. This standard is made by combining 21μL of the 5000 ng/mL PYR 
stock solution with 2079μL of the blank plasma into a labeled centrifuge tube, which results in a 
total volume of 2100μL. Then 1400μL of this solution is used to make the 40 ng/mL, which 
leaves a remaining volume of 700μL for the 50 ng/mL standard. The rest of the standard solutions 
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are made following this serial dilution pattern. Two sets of calibration curves are prepared 
following these instructions: one for the calibration curve and the other for the quality control 
samples. 
 
Table 1. Calibration Curve and Quality Control Sample Preparation Chart 
 
Calibration 
Standard 
(ng/mL) 
Solution 
Used 
Spike 
Volume 
(µL) 
Plasma 
Volume 
(µL) 
Final 
Volume 
(µL) 
Remaining 
Volume 
(µL) 
50 5000 21 2079 2100 700 
*40 50 1400 350 1750 700 
25 40 1050 630 1680 720 
*15 25 960 640 1600 700 
10 15 900 450 1350 755 
*5 10 595 595 1190 700 
2.5 5 490 490 980 700 
1 2.5 280 420 700 700 
*QC 
 
 
Total 5654 
 
  
This table represents the formula for how to prepare the standard curve and qualitative control samples.  
The far left column represents the range of concentrations included in the calibration curve. The asterisks 
represent the quality control samples. 
 
 While the curve is being prepared, patient samples should be removed from the -80 °C 
freezer to thaw for approximately one hour. Once the curve is prepared and the patient samples 
have thawed, the standards and patient samples are mixed with the internal standard solution. 
Adding internal standard into the individual samples allows for the quantification or 
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determination of the exact concentration of PYR in each sample. The internal standard and 
sample mixture is made by adding 500μL of the citrate phosphate internal standard solution to 
500μL of the standard solution, quality control sample, or patient plasma sample in 1.5mL 
centrifuge tubes that are labeled with identifiable information. Blank and double blank samples 
are included in the batch to check for carryover of PYR from the standard samples. The blank 
was made by mixing 500μL of the citrate phosphate internal standard solution and 500μL of 
blank plasma. The double blank was made by mixing 500μL of citrate phosphate buffer and 
500μL of blank plasma. 
 3.5.2 SPE Instructions 
 The WCX cartridge columns are set in a stand above a waste collection dish and labeled 
with the corresponding names of samples that will be eluted through them. These columns are 
conditioned using methanol and the 50mM citrate phosphate buffer solution. To begin this 
process, 2 mL of methanol is added to each column. Once the methanol has completely eluted 
through each column, 2 mL of citrate phosphate buffer is added to each column. After these two 
solutions have gone through the columns, the standard curve, quality control, and patient samples 
are slowly inserted into their designated columns. These samples are eluted at one drop per 
second using the positive pressure manifold until each sample has cleared the column. To rid the 
column of any compound other than PYR and the internal standard, the columns are then washed 
with 1 mL of the citrate phosphate buffer followed by 1 mL of methanol. After the methanol 
wash is complete, the columns are dried under maximum pressure for 30 minutes by the positive 
pressure manifold.  
 Culture tubes are positioned below the SPE columns for the elution of PYR and the 
internal standard. One mL of the elution buffer is added to each column and pushed through with 
the positive pressure manifold at approximately one drop per second. The elution buffer is used to 
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pull PYR and the internal standard from the SPE column to be analyzed. These eluent samples 
are then placed on the sample concentrator at 20 psi for about one hour or until they are 
completely dry. Then, 100 μL of sample diluent is added to each of the culture tubes and vortexed 
for 10 seconds to reconstitute the drug standards and patient samples. These reconstituted samples 
are placed into 150 μL inserts inside 1.5 mL autosampler vials to be put onto the LC-MS/MS 
instrument for analyzation. 
3.6 LC-MS/MS Method Development 
 After the extraction phase has been completed, the final product needs to be analyzed to 
confirm the presence and the amount of analyte in the sample. The LC-MS/MS instrument 
provides a way to separate and analyze chemicals in a mixture. The LC portion of the instrument 
uses mobile phases that flow through the instrument’s tubing and column to carry the sample 
through the instrument. The LC column has an interior surface that has affinities for specific 
compounds. The differences in affinities between the compounds and column help to separate 
samples with multiple compounds. The MS portion of the instrument is set to detect specific 
mass-to-charge ratios for the compounds and ions that come off of the LC column at their 
respective times of elution. The MS provides a way to monitor which drugs elute through the 
column at what time. These results are displayed on a chromatograph.  
 3.6.1 LC Parameters and Conditions 
 The conditions used for the LC include a binary flow pumping mode with a total flow of 
0.5 mL/min that is set at a 70% Pump B concentration, which means that 70% of the total flow 
will be from the MPB solution. The oven temperature was set for 40 °C and a maximum 
temperature of 90 °C. The settings for the autosampler are shown in Table 2, and the time 
program for the instrument is displayed in Table 3. 
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Table 2. LC Autosampler Settings 
Rinsing Volume 200 μL 
Needle Stroke 52 mm 
Rinsing Speed 35 μL/sec 
Sampling Speed 15.0 μL/sec 
Purge Time 25.0 min 
Rinse Dip Time 3 sec 
Rinse Mode Before and after aspiration 
Cooler Temperature 15 °C 
Control Vial Needle Stroke 52 mm 
 
This table shows all of the autosampler settings used for the LC-MS/MS method. 
 
Table 3. Time Program for the LC-MS/MS Method 
 Time Module Event Parameter 
1 6.10 Pumps Pump B Conc. 70 
2 6.10 Pumps Total Flow 0.5 
3 6.11 Pumps Pump B Conc. 5 
4 6.11 Pumps Total Flow 0.7 
5 7.10 Pumps Pump B Conc. 5 
6 7.11 Pumps Pump B Conc. 95 
7 8.10 Pumps Pump B Conc. 95 
8 8.11 Pumps Pump B Conc. 70 
9 8.11 Pumps Total Flow 0.7 
10 8.20 Pumps Total Flow 0.5 
11 9.00      Controller Stop  
 
This table represents the time program used for the LC-MS/MS method. The time column represents the 
exact time in minutes that a specific event will occur whether that is a change in Pump B concentration or a 
change in the total flow rate.  
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 3.6.2 MS Parameters and Conditions 
 The MS conditions are a scan type of multiple reaction monitoring (MRM) with a 
positive polarity. The total scan time is 0.42 seconds, and the total method lasts for 9.003 
minutes. For this MS method, there are 1286 cycles, and each cycle is 0.42 seconds. Table 4 
shows the MRM data for both the parent and daughter ions of PYR and neostigmine. This table 
also shows the MS parameters necessary for each ion. 
 
Table 4. MRM Data for PYR and Neostigmine (NEO) 
 ID Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(msec) 
DP 
(Volts) 
CE 
(Volts) 
CXP 
(Volts) 
1 PYR 182.214 71.700 100.0 46.000 35.000 10.000 
2 PYR 182.214 125.100 100.0 46.000 25.000 18.000 
3 NEO 223.200 150.000 100.0 40.000 49.000 0.000 
4 NEO 223.200 56.000 100.0 40.000 83.000 8.000 
 
The data represented in this table are the MRM and MS settings for this method. The parent ions for PYR 
and NEO are the mass-to-charge ratios listed in the Q1 column, and their daughter ions are the ones shown 
in the Q3 column. The DP, CE, and CXP columns represent the MS settings necessary to detect each ion. 
 
 
3.7 Data Analysis 
 The data collected from the LC-MS/MS method include the peaks for every compound 
injected, which are the calibration curve standards, the quality control samples, and the patient 
plasma samples. The chromatogram peaks were integrated for each sample. Also, the resulting 
concentrations for each sample were calculated by the software and then recorded in an Excel log. 
Figure 2 represents an example of a chromatograph for the 50 ng/mL standard. The MultiQuant® 
software was used to integrate and quantify each sample. 
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Figure 2. Chromatogram of the 50 ng/mL Standard 
 
This figure displays a chromatogram for the 50 ng/mL standard in the calibration curve. The vertical axis is 
the intensity of the peak, and the horizontal axis is the time in minutes. Each of the two peaks represents a 
different compound. The blue peak is the PYR peak, and the red peak within it is a qualifier ion used to 
confirm that the compound is PYR. The green peak is the internal standard peak, and the grey peak within 
it is also a qualifier ion. The retention times for PYR and the internal standard are 4.9 and 5.3 minutes, 
respectively.   
 
3.8 Validation 
 Validation for this experimental methodology followed the guidelines made by the 
Scientific Working Group for Forensic Toxicology (SWGTOX). The validation for this method 
included studies on linearity, accuracy, precision, matrix effects, process efficiency, recovery 
efficiency, interference, carryover, and stability. Results for each of these studies fell within the 
required ranges. 
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3.9 Conclusion 
 The experimental methodology for this study was to conduct an extraction for PYR in 
plasma and then perform LC-MS/MS analysis on the resulting samples. Blank plasma was 
properly prepared for use to make the calibration curve standards and qualitative control samples. 
All samples were added to an internal standard solution, so that the exact concentration of each 
sample could be calculated. Each sample was then extracted by SPE to separate PYR and the 
internal standard from the undesired chemicals in the plasma matrix. The extracted samples were 
then injected into the LC/MS instrument to determine the concentrations of the calibration curve, 
qualitative control, and patient samples. Analyst® and MultiQuant® were used to control the 
instruments and perform data analysis.  
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CHAPTER IV 
 
 
FINDINGS 
 
4.1 Calibration Curve 
 The project began with testing and validating the calibration curve. Figure 3 displays the 
first attempt at the calibration curve. This curve produced two outliers. The second attempt at the 
curve also produced outliers. Figure 4 shows the second attempt at the calibration curve. 
 
Figure 3. Calibration Curve from 1/20/2016 
 
This calibration curve was the first attempt at the process. The standard values 2.5 and 15 ng/mL (the 
points that are not filled in) were removed from the curve because they were outliers. The y-axis represents 
the area ratio between the standard and the internal standard, and the x-axis represents the concentration 
ratio between the standard and the internal standard. 
 
With these random outliers appearing in different standard positions, a change to the plasma  
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preparation was made, which is the preparation mentioned in the method section. The original 
preparation only thawed the blank plasma before preparing the calibration curve, which left 
proteins and clotting factors that clogged the SPE columns not allowing all the drug to elute 
through.  
 
Figure 4. Calibration Curve from 2/1/2016 
 
The second attempted calibration curve produced at least two outliers: the 25 and 40 ng/mL samples. 
 
 The calibration curves after the plasma preparation method change produced better 
linearity, which meant that the calibration curve could be validated. Figures 5, 6, 7 display the 
reproducible calibration curves that led to the validation of the method.  
 
Figure 5. Calibration Curve from 2/17/2016 
 
This calibration curve was the first attempt after implementing the new plasma preparation method. Every 
point in the curve is within 15% of the expected concentration.  
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Figure 6. Calibration Curve from 3/1/2016 
 
Figure 6 represents the first successful replication of the calibration curve after the plasma preparation 
method implementation. Again, every point is within 15% of the expected concentration and there are no 
distinct outliers. 
 
Figure 7. Calibration Curve from 3/22/2016 
 
Figure 7 represents the final successful replication of the calibration curve before the validation began. 
Once again, each point is within 15% of the expected concentration.  
 
4.2 Validation Results 
 Next the calibration curve and LC-MS/MS method were validated according to 
SWGTOX guidelines, and the data and results for each validation phase are reported below.  
 4.2.1 Linearity 
 Table 5 represents the data taken for the seven calibration curves tested for linearity.  
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Table 5. Linearity Data for Calibration Curve Validation 
Concentration 
(ng/mL) 
Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Run 7 Average 
Absolute 
Error (%) 
50 55.3 52.03 55.00 53.25 56.18 53.99 52.03 53.97 7.94 
40 40.4 41.39 39.67 39.67 38.96 40.88 40.71 40.23 0.58 
25 24.7 23.43 24.86 24.78 24.57 25.08 25.52 24.70 1.20 
15 15.6 15.56 15.08 15.22 15.50 15.68 15.32 15.41 2.73 
10 10.1 10.23 9.92 10.13 10.26 10.48 10.26 10.20 2.00 
5 5.14 4.97 5.34 5.33 5.29 5.10 5.19 5.20 4.00 
2.5 2.59 2.56 2.65 2.60 2.59 2.64 2.55 2.60 4.00 
1 0.90 0.92 0.91 0.89 0.92 0.95 0.99 0.93 7.00 
Blank* 0 0 0 0 0 0 0 0  
R2 0.995 0.998 0.995 0.998 0.991 0.998 1.000 0.996  
This table displays the data from the linearity study for the calibration curve. The far left column lists the 
expected concentration value, and the columns below Runs 1-7 list the actual values from the individual 
runs. The R2 value for each run is above 0.99. The percent absolute error for each standard point is less than 
10%. The results from this study validate the calibration curve’s linearity. 
 
 4.2.2 Accuracy 
 The accuracy studies were completed using the values of the quality control (QC) 
standards from five different run days. Each QC standard was run at least four times each day 
with the calibration curve and patient samples. Tables 6-8 provide the accuracy data for each QC 
standard. The overall accuracy for all of the QCs was 101%.  
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Table 6. Accuracy Data for 40 ng/mL Quality Control Standard 
Day # Result 1 Result 2 Result 3 Result 4 Daily Mean 
Daily Mean 
Accuracy 
(%) 
1 42.3 41.0 34.9 38.3 39.1 98% 
2 37.6 38.0 38.3 38.1 38.0 95% 
3 37.0 43.8 41.7 41.1 40.9 102% 
4 39.4 36.9 36.4 37.7 37.6 94% 
5 42.9 36.0 41.1 38.3 39.6 99% 
     Average 98% 
Table 6 displays the data for QC 1, which is 40 ng/mL pyridostigmine. The average accuracy percentage 
for all runs was 98%, and the range of values for accuracy % were 94-102%.  
 
Table 7. Accuracy Data for 15 ng/mL Quality Control Standard 
Day # Result 1 Result 2 Result 3 Result 4 Daily Mean 
Daily Mean 
Accuracy 
(%) 
1 16.2 15.7 14.3 15.1 15.3 102% 
2 14.6 14.4 14.7 14.6 14.6 97% 
3 13.9 15.4 15.8 15.3 15.1 101% 
4 15.0 14.9 14.5 15.2 14.9 99% 
5 15.8 14.2 15.6 14.8 15.1 101% 
     Average 100% 
Table 7 displays the data for QC 2, which is 15 ng/mL pyridostigmine. The average accuracy percentage 
for all five runs was 100%, and the range of accuracy percentage values was 97-102%. 
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Table 8. Accuracy Data for 5 ng/mL Quality Control Standard 
Day # Result 1 Result 2 Result 3 Result 4 Daily Mean 
Daily Mean 
Accuracy 
(%) 
1 5.1 5.7 5.1 5.2 5.3 106% 
2 5.1 5.2 5.0 5.1 5.1 102% 
3 5.2 5.5 5.6 5.5 5.5 109% 
4 5.5 5.5 5.4 5.5 5.5 109% 
5 5.6 5.1 5.4 5.3 5.3 107% 
     Average 106% 
Table 8 represents the data for QC 3, which is 5 ng/mL pyridostigmine. The average accuracy percentage 
for all five runs was 106%, which is within 10% of the expected concentration. The range of accuracy 
percentages was 102-109%, so no day had a mean accuracy percentage more than 10% away from the 
desired result. 
 
 4.2.3 Precision 
 The data used for the precision studies were from the same set of QC standards used for 
the accuracy study. Table 9 shows the results for within-run, between run, within-laboratory, 
interday, and intraday precision for each QC standard.  
 
Table 9. Precision Data for All Quality Control Standards 
Imprecision 40 ng/mL 15 ng/mL 5 ng/mL 
Within-Run Precision 6.20 4.03 4.22 
Between Run Precision 4.16 3.20 2.18 
Within-Laboratory 
Precision 
6.22 4.11 4.49 
Interday Precision 1.45 1.22 2.56 
Intraday Precision 1.38 1.46 2.04 
 
Table 9 displays the precision results for all QC standards. Each value for precision is beneath 15, which is 
the acceptable limit.  
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4.2.4 Matrix Effects, Recovery Efficiency, and Process Efficiency 
 The data listed in Table 12 are from the individual runs for the neat, post-extraction, and 
pre-extraction samples. The data from these three different extraction types were used to 
determine matrix effects (ME), recovery efficiency (RE), and process efficiency (PE). The neat 
samples are pyridostigmine samples at 25 ng/mL made in methanol and injected directly onto the 
instrument without extraction. The post-extraction samples are blank plasma samples are 
reconstituted with the 25 ng/mL methanol standard after the full extraction process, and the pre-
extraction samples are 25 ng/mL samples made following the actual method procedure. Table 13 
lists the results from each study.  
 
Table 10. ME, RE, and PE Data 
 
Neat Area Post Area Pre Area 
Sample1 2.4E+06 2.8E+06 2.4E+06 
Sample2 2.5E+06 2.6E+06 2.6E+06 
Sample3 2.4E+06 2.5E+06 2.5E+06     
 
Neat Area Post Area Pre Area 
Average 2.4E+06 2.7E+06 2.5E+06 
Table 12 shows the data from each extraction. The areas for each of the three samples for the neat, post-
extraction, and pre-extraction runs are listed, and the averages for each are given at the bottom of the table. 
  
Table 11. Results from ME, RE, and PE Study 
Matrix Effect (%) Recovery Efficiency (%) Process Efficiency (%) 
110 93.8 103 
Table 13 shows the results for each of the three studies. The matrix effect percentage was calculated by 
dividing the post-extraction average area by the neat average area and then multiplying by 100. The 
recovery efficiency percentage was calculated by dividing the pre-extraction average area by the post-
extraction average area and then multiplying by 100. Finally, the process efficiency percentage was 
calculated by dividing the pre-extraction average area by the neat average area and then multiplying by 
100. All values are roughly within 10% of 100%, which is better than the values that are needed for 
validity. 
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 4.2.5 Stability 
 The stability study tests a 40 ng/mL sample’s stability on the instrument following three 
days. Table 14 provides the data for each injection on the instrument for each day.  
 
Table 12. Stability Study Data 
Date Sample ID Area 
Ratio of 
PYR to NEO 
Absolute 
Error (%) 
7/28/16 PYR 1 3.05E+07 0.970 0 
 PYR 2 1.29E+07 0.638 0 
 NEO 1 3.15E+07   
 NEO 2 2.02E+07   
7/29/16 PYR 1 4.50E+07 0.974 0.47 
 PYR 2 1.85E+07 0.607 4.84 
 NEO 1 4.62E+07   
 NEO 2 3.04E+07   
7/30/16 PYR 1 4.24E+07 0.997 2.83 
 PYR 2 1.72E+07 0.634 0.56 
 NEO 1 4.25E+07   
 NEO 2 2.72E+07   
Table 14 provides the data for the stability study. PYR and NEO stand for pyridostigmine and neostigmine, 
and the 1 and 2 represent the two daughter ions detected by the mass spectrometer. The ratios for PYR 1 to 
NEO 1 and PYR 2 to NEO 2 were determined for each day. The absolute error percentage was calculated 
for 7/29 and 7/30 comparing them to the 7/28 run. All percentages are within 5% of the first day’s ratios, 
which means that the on-instrument stability for this extracted drug is acceptable. 
 
 4.2.6 Carryover 
 The carryover study was done to make sure that pyridostigmine was not staying on the 
column between runs, which could cause the next calculated concentration to be higher than in 
actuality. Carryover was tested by injecting the 50 ng/mL standard and then a blank sample to 
make sure that no drug was detected in the blank. The data for this study is shown in Table 15. 
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Table 13. Carryover Study Data 
Concentration Sample Area 
50 PYR 1 1.40E+07 
50 PYR 2 5.54E+06 
50 NEO 1 3.47E+07 
50 NEO 2 2.22E+07 
Blank PYR 1 N/A 
Blank PYR 2 N/A 
Blank NEO 1 3.40E+07 
Blank NEO 2 2.21E+07 
50 PYR 1 2.34E+07 
50 PYR 2 9.59E+06 
50 NEO 1 3.27E+07 
50 NEO 2 2.07E+07 
Blank PYR 1 N/A 
Blank PYR 2 N/A 
Blank NEO 1 3.34E+07 
Blank NEO 2 2.10E+07 
50 PYR 1 2.18E+07 
50 PYR 2 9.08E+06 
50 NEO 1 3.26E+07 
50 NEO 2 2.11E+07 
Blank PYR 1 N/A 
Blank PYR 2 N/A 
Blank NEO 1 3.21E+07 
Blank NEO 2 2.12E+07 
Table 15 provides the data for the carryover study. Pyridostigmine was not detectable in any blank run, 
which means that there is no carryover of this drug with this method and column. 
 
 4.2.7 Interference 
 The final validity study conducted was the interference study. This study compared an 
extracted 40 ng/mL sample of pyridostigmine with an extracted 40 ng/mL sample that had fifty-
seven other drugs added. This interference study was conducted to ensure that the patient 
concentrations of pyridostigmine would not be influenced by other drugs that the patient could be 
taking. Table 16 provides the interference study data. 
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Table 14. Interference Study Data 
Concentration 
(ng/mL) 
Sample 
ID 
Area Ratio of PYR 
to NEO 
 Error (%) 
40 PYR 1 3.25E+07 0.816  
40 PYR 2 1.33E+07 0.518  
40 NEO 1 3.98E+07   
40 NEO 2 2.58E+07   
40 (Interference) PYR 1 2.40E+07 0.788 -3.46 
40 (Interference) PYR 2 9.54E+06 0.494 -4.55 
40 (Interference) NEO 1 3.05E+07   
40 (Interference) NEO 2 1.93E+07   
Table 16 provides the data for the interference study. The absolute error percentages for the interference 
sample were each less than 5%. Also, each ratio decreased by about the same percentage, which drug 
interference should not be a problem when calculating pyridostigmine’s concentration.  
 
4.3 Patient Data 
 The calibration curves, Figures 8-14, and patient results, Tables 17-23, are provided for 
each day that patient samples were extracted and quantified. 
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Figure 8. Calibration Curve for Patient Samples Ran on 4/6/2016 
 
Figure 8 provides the graph for the calibration curve that accompanied patients 51 and 008. All standards 
and QCs fell within 15% of their expected values. 
Table 15. Patient Data for 4/6/2016 
Patient ng/mL Patient ng/mL 
51-1 V2 N/A 008-01 V2 N/A 
51-1 V3 N/A 008-01 V3 N/A 
51-2 V3 7.67 008-02 V3 8.01 
51-1 V4 N/A 008-01 V4 11.4 
51-2 V4 N/A 008-02 V4 8.59 
51-1 V5 9.90 008-01 V5 1.93 
51-2 V5 9.79 008-02 V5 3.29 
51-3 V5 16.2 008-03 V5 5.83 
51-1 V6 N/A 008-01 V6 26.6 
51-2 V6 N/A 008-02 V6 17.7 
51-1 V7 N/A 008-01 V7 10.7 
51-2 V7 3.29 008-02 V7 19.0 
51-3 V7 27.7 008-03 V7 40.4 
51-1 V8 N/A 008-01 V8 24.5 
51-2 V8 N/A 008-02 V8 21.4 
51-1 V9 N/A 
51-1 V10 N/A 
51-2 V10 N/A 
51-1 V11 N/A 
51-2 V11 N/A 
51-1 V12 N/A 
Table 17 provides the concentration of pyridostigmine in each of the plasma samples for patients 51 and 
008. The   V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the order that 
the samples were taken from the patient on that visit. The value N/A indicates that no pyridostigmine was 
detected in that sample. 
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Figure 9. Calibration Curve for Patient Samples Ran on 4/12/2016 
 
Figure 9 provides the graph for the calibration curve that accompanied patients 49 and 007. All standards 
and QCs fell within 15% of their expected values. 
 
Table 16. Patient Data for 4/12/2016 
Patient ng/mL Patient ng/mL 
49-1 V2 N/A 007-01 V2 N/A 
49-1 V3 N/A 007-01 V3 N/A 
49-2 V3 3.01 007-02 V3 4.42 
49-1 V4 12.7 007-01 V4 4.50 
49-2 V4 12.1 007-02 V4 8.87 
49-1 V5 12.3 007-01 V5 10.6 
49-2 V5 13.7 007-02 V5 9.59 
49-3 V5 16.7 007-03 V5 20.2 
49-1 V6 17.8 007-01 V6 13.3 
49-2 V6 17.9 007-02 V6 18.5 
49-1 V7 19.3 007-01 V7 14.1 
49-2 V7 17.9 007-02 V7 15.4 
49-3 V7 29.0 007-03 V7 28.0 
49-1 V8* Not Quantifiable 007-01 V8 39.4 
49-2 V8* Not Quantifiable 007-02 V8 28.5 
49-1 V9* Not Quantifiable 
49-1 V10 24.9 
49-2 V10 19.7 
49-1 V11 24.0 
49-2 V11 21.3 
49-1 V12 N/A 
Table 18 provides the concentration of pyridostigmine in each of the plasma samples for patients 49 and 
007. The V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the order that 
the samples were taken from the patient on that visit. The value N/A indicates that no pyridostigmine was 
detected in that sample. Samples with asterisks were unable to be quantified with pyridostigmine peaks 
present, so they were diluted and rerun in a later batch.
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Figure 10. Calibration Curve for Patient Samples Ran on 4/15/2016 
 
Figure 10 provides the graph for the calibration curve that accompanied patients 33 and 24. All standards 
and QCs fell within 15% of their expected values. 
 
Table 17. Patient Data for 4/15/2016 
Patient ng/mL Patient ng/mL 
33-1 V2 N/A 24-1 V2 N/A 
33-1 V3 N/A 24-1 V3 N/A 
33-2 V3 9.38 24-2 V3 6.62 
33-1 V4 5.94 24-1 V4 11.3 
33-2 V4 5.00 24-2 V4 9.56 
33-1 V5 8.04 24-1 V5 6.32 
33-2 V5 7.00 24-2 V5 7.46 
33-3 V5 8.43 24-3 V5 10.2 
33-1 V6 12.9 24-1 V6 14.2 
33-2 V6 19.9 24-2 V6 10.4 
33-3 V6 20.3 24-1 V7 8.41 
33-1 V7 15.7 24-2 V7 6.46 
33-2 V7 12.2 24-3 V7 11.9 
33-3 V7 25.5 24-1 V8 33.8 
33-1 V8 26.1 24-2 V8 28.8 
33-2 V8 20.1 24-1 V9 31.1 
33-1 V9 23.7 24-1 V10 8.18 
33-1 V10 10.1 24-2 V10 12.4 
33-2 V10 8.20 24-1 V11 4.33 
33-1 V11 12.4 24-2 V11 8.27 
33-2 V11 10.2 24-1 V12 N/A 
33-1 V12 N/A 
Table 19 provides the concentration of pyridostigmine in each of the plasma samples for patients 33 and 
24. The     V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the order that 
the samples were taken from the patient on that visit. The value N/A indicates that no pyridostigmine was 
detected in that sample. 
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Figure 11. Calibration Curve for Patient Samples Ran on 4/23/2016 
 
Figure 11 provides the graph for the calibration curve that accompanied patients 44 and 40. All standards 
and QCs fell within 15% of their expected values. 
 
Table 18. Patient Data for 4/23/2016 
Patient ng/mL Patient ng/mL 
44-1 V2 N/A 40-1 V2 N/A 
44-1 V3 N/A 40-2 V3 3.90 
44-2 V3 10.6 40-1 V4 11.6 
44-1 V4 7.65 40-2 V4 10.7 
44-2 V4 6.83 40-1 V5 6.65 
44-1 V5 N/A 40-2 V5 17.3 
44-2 V5 2.25 40-3 V5 18.9 
44-3 V5 14.4 40-1 V6 19.0 
44-1 V6 25.8 40-2 V6 13.5 
44-2 V6 23.0 40-1 V7 11.6 
44-1 V7 25.4 40-2 V7 29.0 
44-2 V7 22.3 40-3 V7 24.4 
44-3 V7 34.6 40-1 V8 14.8 
44-1 V8 25.4 40-2 V8 13.2 
44-2 V8 23.0 40-1 V9 23.7 
44-1 V9 33.0 40-1 V10 17.2 
44-2 V9 27.6 40-2 V10 15.1 
44-1 V10 19.6 40-1 V11 7.43 
44-2 V10 22.9 40-2 V11 5.64 
44-1 V11 13.3 40-1 V12 N/A 
44-2 V11 9.43 
44-1 V12 N/A 
Table 20 provides the concentration of pyridostigmine in each of the plasma samples for patients 44 and 
40. The     V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the order that 
the samples were taken from the patient on that visit. The value N/A indicates that no pyridostigmine was 
detected in that sample. 
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Figure 12. Calibration Curve for Patient Samples Ran on 5/11/2016 
 
Figure 12 provides the graph for the calibration curve that accompanied patients 35, 31, and 12. All 
standards and QCs fell within 15% of their expected values. 
 
Table 19. Patient Data for 5/11/2016 
Patient ng/mL Patient ng/mL Patient ng/mL 
35-1 V2 N/A 31-1 V2 N/A 12-1 V2 N/A 
35-2 V3 7.21 31-1 V3 N/A 12-1 V3 N/A 
35-1 V4 14.4 31-2 V3 15.7 12-2 V3 7.54 
35-2 V4 12.6 31-1 V4 1.41 12-1 V4 16.5 
35-1 V5 9.21 31-2 V4 4.52 12-2 V4 14.6 
35-2 V5 7.02 31-1 V5 11.8 12-1 V5 12.0 
35-3 V5 8.63 31-2 V5 18.8 12-2 V5 7.94 
35-1 V6 17.0 31-3 V5 19.9 12-3 V5 9.30 
35-2 V6 15.6 31-1 V6 12.2 12-1 V6 10.8 
35-1 V7 20.9 31-2 V6 5.35 12-2 V6 9.39 
35-2 V7 19.9 31-1 V7 13.6 12-1 V7 3.35 
35-3 V7 29.3 31-2 V7 11.6 12-2 V7 7.38 
35-1 V8 22.7 31-3 V7 47.4 12-3 V7 7.38 
35-2 V8 21.2 31-1 V8 12.3 12-1 V8 8.00 
35-1 V9 15.2 31-2 V8 9.28 12-2 V8 5.98 
35-2 V9 15.0 31-1 V9 17.1 12-1 V9 4.51 
35-1 V10 16.7 31-1 V10 7.09 12-1 V12 N/A 
35-2 V10 21.4 31-2 V10 6.94 
35-1 V11 12.1 31-1 V12 N/A 
35-2 V11 12.0 
35-1 V12 N/A 
Table 21 provides the concentration of pyridostigmine in each of the plasma samples for patients 35, 31, 
and 12. The     V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the order 
that the samples were taken from the patient on that visit. The value N/A indicates that no pyridostigmine 
was detected in that sample. 
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Figure 13. Calibration Curve for Patient Samples Ran on 5/15/2016 
 
Figure 13 provides the graph for the calibration curve that accompanied patients 009, 23, 001, 11, and 28. 
All standards and QCs fell within 15% of their expected values. 
 
Table 20. Patient Data for 5/15/2016 
Patient ng/mL Patient ng/mL Patient ng/mL 
009-1 V2 N/A 11-1 V3 N/A 28-1 V2 N/A 
009-1 V3 N/A 11-2 V3 8.50 28-1 V3 N/A 
009-2 V3 9.99 11-1 V4 25.6 28-2 V3 7.92 
009-1 V8 19.6 11-2 V4 26.7 28-1 V4 16.7 
009-2 V8 15.9 11-1 V5 17.6 28-2 V4 17.4 
009-1 V9 30.7 11-2 V5 16.8 28-1 V5 5.58 
009-1 V10 11.0 11-3 V5 33.8 28-2 V5 5.62 
009-2 V10 8.65 11-1 V6* Not Quantifiable 28-3 V5 25.4 
009-1 V11 N/A 11-2 V6* Not Quantifiable 28-1 V6* Not Quantifiable 
23-2 V2 N/A 11-1 V7* Not Quantifiable 28-2 V6 38.1 
23-1 V5 1.15 11-2 V7* Not Quantifiable 28-1 V7 25.6 
23-2 V5 7.35 11-3 V7* Not Quantifiable 28-2 V7 34.5 
23-3 V5 15.2 11-1 V8* Not Quantifiable 28-3 V7* Not Quantifiable 
23-1 V6 10.5 11-2 V8* Not Quantifiable 28-1 V9 N/A 
23-2 V6 8.20 11-1 V9* Not Quantifiable 28-1 V10 19.1 
001-1 V3 N/A 11-1 V10 32.9 28-2 V10 14.6 
001-2 V3 4.88 11-2 V10 35.3 28-1 V11 2.47 
001-1 V4 13.5 11-1 V11 23.4 28-2 V11 1.78 
001-2 V4 12.5 11-2 V11 27.9 28-1 V12 N/A 
001-1 V5 9.03 11-1 V12 N/A 
001-1 V9 N/A 
Table 22 provides the concentration of pyridostigmine in each of the plasma samples for patients 009, 23, 
001, 11, and 28. The V followed by a number indicates the visit number, and the 01, 02, and 03 indicate the 
order that the samples were taken from the patient on that visit. The value N/A indicates that no 
pyridostigmine was detected in that sample. Samples with asterisks were unable to be quantified with 
pyridostigmine peaks present, so they were diluted and rerun in the next batch. 
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Figure 14. Calibration Curve for Diluted Patient Samples Ran on 5/27/2016 
 
Figure 14 provides the graph for the calibration curve that accompanied the samples that needed to be 
diluted. All standards and QCs fell within 15% of their expected values. 
 
Table 21. Patient Data Following Dilution on 5/27/2016 
Patient ng/mL Diluted 
49-1 V8 88.1 8.81 
49-2 V8 67.2 6.72 
49-1 V9 82.5 8.25 
28-1 V6 32.1 3.21 
28-3 V7 47.0 4.70 
11-1 V6 9.34 0.93 
11-2 V6 10.1 1.01 
11-1 V7 14.2 1.42 
11-2 V7 39.1 3.91 
11-3 V7 82.9 8.29 
11-1 V8 13.4 1.34 
11-2 V8 7.46 0.75 
11-1 V9 13.5 1.35 
Table 23 provides the dilution information for the patients whose samples were unable to be quantified in 
earlier runs. All samples were diluted by a factor of 10, so the concentrations under the Diluted column are 
those quantified by the software. The values beneath the ng/mL column are the actual concentrations after 
the dilution is taken out. 
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CHAPTER V 
 
 
CONCLUSION 
 
5.1 Discussion 
 PYR has already proved that it is a useful AChE inhibitor by helping with myasthenia 
gravis patients and soldiers during the Gulf War that were threatened with nerve agent attacks. 
Recently, it has also proven its effectiveness as a cardiac aid. The results from this research 
provide quantitative data from patients taking specific doses of this drug. This data provides the 
means to determine a proper dosing regimen so that this drug can be taken by and provided to 
patients correctly.  
 This study also provides a method for treating blank plasma before SPE. The original 
method was to thaw and then use the thawed plasma to prepare the calibration curve. However, 
the large proteins and clotting factors within the plasma clogged the SPE columns, which 
inhibited all of PYR from eluting through the column. The clogged columns led to poor and 
inconsistent calibration curves with low intensities for each standard. However, when the method 
was altered to thawing, sonicating, centrifuging, and then filtering the plasma, cleaner plasma was 
produced that kept the columns for clogging. This new method then allowed for the calibration 
curve to be validated. 
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5.2 Conclusion 
 The LC-MS/MS method was successful in detecting and quantifying PYR in the cardiac 
patient plasma samples. The plasma preparation and SPE methods were able to provide clean 
samples to be analyzed on the LC-MS/MS instrumentation. The results from this study provide 
the quantified PYR sample data needed to help determine proper dosing for future clinical 
patients. This study also provides a successful extraction and LC-MS/MS method that could be 
incorporated into any future lab that may need to quantify PYR in human plasma.  
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